Roche's phase III AVAglio study meets co─primary endpoint of significantly improving PFS in people with glioblastoma
08:57 EDT 11 Aug 2012 | PharmaBiz
Roche has reported that the phase III AVAglio study of Avastin plus radiation and temozolomide chemotherapy in people with newly diagnosed glioblastoma met its co─primary endpoint of a significant improvement in progression─free survival (PFS).
Original Article: Roche's phase III AVAglio study meets co─primary endpoint of significantly improving PFS in people with glioblastoma
More From BioPortfolio on "Roche's phase III AVAglio study meets co─primary endpoint of significantly improving PFS in people with glioblastoma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
